Thalidomide in the Management of Multiple Myeloma

References

• Solly, S. (1844) "Remarks on the pathology of mollities ossium with cases", Med.-Chir. Trans. Lond. 27, 435–461.
   PubMedGoogle Scholar
• Greenlee, R.T., Murray, T., Bolden, S. and Wingo, PA. (2000) "Cancer Statistics", CA Cancer J. Clin. 50, 7–33.
   PubMed Web of Science ®Google Scholar
• Incidence of Haematological Malignancies in 2000, Report of the South Thames Haematology Specialist Committee and the Thames Cancer Registry. 2002, Kings College, London.
   Google Scholar
• Oken, M.M. (1994) "Standard treatment of multiple mye-loma", Mayo Clin. Proc. 69, 781–786.
   PubMed Web of Science ®Google Scholar
• Alexanian, R. and Dimopoulos, M. (1994) "The treatment of multiple myeloma", N. Engl. J. Med. 330(5), 484–489.
   PubMedGoogle Scholar
• Bergsagel, D.E., Sprague, C.C., Austin, C. and Griffith, K.H. (1962) "Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma IV. L-Phenylanaline mustard (NSC-8806)", Cancer Chemother. Rep. 21, 87–99.
   PubMedGoogle Scholar
• Korst, D.R., Clifford, GO., Fowler, W.M., et al. (1964) "Multiple myeloma II. Analysis of cyclophosphamide therapy in 165 patients", J. Am. Med. Assoc. 189, 758–762.
   PubMed Web of Science ®Google Scholar
• Sporn, J.R. and McIntyre, O.R. (1980) "Chemotherapy of previously untreated myeloma patients: an analysis of recent treatment results", Semin. Oncol. 13, 318–325.
   Google Scholar
• MacLennan, IC., Chapman, C., Dunn, J. et al. (1992) "Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults", Lancet 339(8787), 200–205.
   PubMed Web of Science ®Google Scholar
• Gregory, W.M., Richards, MA. and Malpas, J.S. (1992) "Combination chemotherapy versus melphalan and predni-solone in the treatment of multiple myeloma: an overview of published trials", J. Clin. Oncol. 10(2), 334–342.
   PubMed Web of Science ®Google Scholar
• Kovacsovics, T. and Daly, A. (1997) "Intensive treatment strategies in myeloma", Semin. Haematol. 34, 49–60.
   PubMed Web of Science ®Google Scholar
• Harrousseau, J.L. and Attal, MD. (1997) "The role of autologous haemopoietic stem cell transplantation in mul-tiple myeloma", Semin. Haematol. 34, 61–66.
   PubMed Web of Science ®Google Scholar
• Schlossman, R.L. and Anderson, K.C. (1999) "Bone marrow transplantation in multiple myeloma", Curr. Opin. Oncol. 11(2), 102–108.
   PubMedGoogle Scholar
• Schey, S.A., Kazmi, M., Lahkani, A. and Ireland, R. (1998) "Intermediate dose melphalan and dexamethazone in the treatment of de novo myeloma", Fur. J. Haematol. 61(5), 306–310.
   PubMed Web of Science ®Google Scholar
• Lokhorst, H.M., Sonneveld, P., Wijermans, P.W., et al. (1996) "Intermediate-dose melphalan (IDM) combined with G-CSF (filgrastim) is an effective and safe induction therapy for autologous stem cell transplantation in multiple myeloma", Br. J. Haematol. 92(1), 44–48.
   PubMed Web of Science ®Google Scholar
• Myeloma Trialists Collaborative Group (1998) "Combination chemotherapy versus melphalan plus prednisolone as treatment for multiple myeloma: an overview of 6633 patients from 27 randomised trials", J. Clin. Oncol. 16, 3832–3842.
   PubMedGoogle Scholar
• Oken, UM., Harrington, D.P., Aloramson, N., Kyle, R.A., Knospe, W. and Glick, J.H. (1997) "Comparison of melphalan and prednisolone with vincristine, carmustine, melphalan, cyclophosphamide and prednisolone in the treatment of multiple myeloma: results of Eastern Co-operative Oncology Group Study E2479", Cancer 79, 1561–1571.
   PubMed Web of Science ®Google Scholar
• Besinger, WI., Demirer, T., Buckner, C.D., et al. (1992) "Allogeneic marrow transplantation for multiple myeloma: an analysis of the risk factors on outcome", Blood 88, 2782–2793.
   Google Scholar
• Bjorksrand, B., Ljungman, P., Svensson, H., et al. (1997) "Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma—a retrospective case-matched study from the European Bone marrow Transplant Group (EBMT)", Blood 88, 4711–4718.
   Web of Science ®Google Scholar
• Bjorkstrand, B. (2001) "European Group for Blood and Marrow Transplantation Registry studies in multiple mye-loma", Semin. Hematol. 38(3), 219–225.
   PubMed Web of Science ®Google Scholar
• Attal, M., Harrousseau, US., Stoppa, A.M., et al. (1996) "A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma", N. Engl. J. Med. 335, 91–97.
   PubMed Web of Science ®Google Scholar
• MRC MM VBI. (2001) VIIIth International Myeloma Work-shop Banff, Abstracts S38, May 4–8.
   Google Scholar
• Bjorkstrand, B., Svensson, H., Goldschmidt, H., et al. (2001) "Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT)", Bone Marrow Transplant. 27(5), 511–515.
   PubMed Web of Science ®Google Scholar
• Cunningham, D., Powles, R., Malpas, J., et al. (1998) "A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results", Br. J. Haematol. 102(2), 495–502.
   PubMed Web of Science ®Google Scholar
• Sonneveld, P. (2000) "Multidrug resistance in haematological malignancies", J. Intern. Med. 247(5), 521–534.
   PubMed Web of Science ®Google Scholar
• Hazlehurst, L.A., Foley, N.E., Gleason-Guzman, MC., et al. (1999) "Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line", Cancer Res. 59(5), 1021–1028.
   PubMed Web of Science ®Google Scholar
• Watts, G.S., Futscher, B.W., Isett, R., et al. (2001) "cDNA microarray analysis of multidrug resistance: doxorubicin selection produces multiple defects in apoptosis signaling pathways", J. Pharmacol. Exp. Ther. 299(2), 434–441.
   PubMed Web of Science ®Google Scholar
• Bucaid, AC., Clifford, GO., Fowler, W.M., et al. (1964) "Multiple myeloma II. Analysis of cyclophosphamide therapy in 165 patients", J. Am. Med. Assoc. 189, 758–762.
   Web of Science ®Google Scholar
• Alexanian, R., Barlogie, B. and Dixon, D. (1986) "High dose corticosteroid treatment of resistant myeloma", Ann. Int. Med. 105, 8–11.
   PubMed Web of Science ®Google Scholar
• Hallek, M., Bergsagel, P.L. and Anderson, K.C. (1998) "Multiple myeloma: increasing evidence for a multistep transformation process", Blood 91(1), 3–21.
   PubMed Web of Science ®Google Scholar
• Berenson, JR., Sjak-Shie, N.N. and Vescio, R.A. (2000) "The role of human and viral cytokines in the pathogenesis of multiple myeloma", Semin. Cancer Biol. 10, 383–391.
   PubMed Web of Science ®Google Scholar
• Bellamy, W.T. (2001) "Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other haemopoeitic malignancies", Semin. Oncol. 28,551–559.
   PubMed Web of Science ®Google Scholar
• Gupta, D., Treon, S.P., Shima, Y., et al. (2001) "Adherence of multiple myeloma cells upregulates vascular endothelial growth factor secretion: therapeutic applications", Leukaemia 15, 1950–1961.
   PubMed Web of Science ®Google Scholar
• Vacca, A., Ribatti, D., Presta, M., et al. (1999) "Bone marrow neovascularization, plasma cell angiogenic potential and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma", Blood 93, 3064–3073.
   PubMed Web of Science ®Google Scholar
• Vacca, A., Ribalti, D., Roncali, L., et al. (1994) "Bone marrow angiogenesis and progression in multiple myeloma", Br. J. Haematol. 87, 503–508.
   PubMed Web of Science ®Google Scholar
• Dankbar, B., Padro, T., Leo, R., et al. (2000) "Vascular endothelial growth factor and interleukin 6 in paracrine tumour-stromal cell interactions in multiple myeloma", Blood 95, 2630–2636.
   PubMed Web of Science ®Google Scholar
• Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, H., Kuramoto, A. and Kishimoto, T. (1988) "Autocrine generation and require-ment of BSF-2/IL-6 for human multiple myelomas", Nature 332(6159), 83–85.
   PubMed Web of Science ®Google Scholar
• Fukuihima, Y, Byers, M.G., Fiddes, J.C. and Shows, T.B. (1990) "The human basic fibroblast growth factor gene (bFGF) is assigned to chromosome 4q25", Cytogenet. Cell Genet. 54, 159–160.
   PubMedGoogle Scholar
• Lauta, V.M. (2001) "Interleukin-6 and the network of several cytokines in multiple myeloma: an overview of clinical and experimental data", Cytokine 16(3), 79–86.
   PubMed Web of Science ®Google Scholar
• Szczepek, A.J., Belch, A.R. and Pilarski, L.M. (2001) "Expression of IL-6 and IL-6 receptors by circulating clonotypic B cells in multiple myeloma: potential for autocrine and paracrine networks", Exp. Hematol. 29(9), 1076–1081.
   PubMed Web of Science ®Google Scholar
• Uchiyama, H., Barut, B.A., Mohrbacher, A.F., Chauhan, D. and Anderson, K.C. (1993) "Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion", Blood 82(12), 3712–3720.
   PubMed Web of Science ®Google Scholar
• Chauhan, D., Uchiyama, H., Akbarali, Y., Urashima, M., Yamamoto, K., Libermann, T. and Anderson, K.C. (1996) "Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-KB", Blood 87(3), 1104–1112.
   PubMed Web of Science ®Google Scholar
• Chauhan, D., Kharbanda, S.M., Ogata, A., et al. (1995) "Oncostatin M induces association of Grb2 with Janus kinase JAK2 in multiple myeloma cells", J. Exp. Med. 182(6), 1801–1806.
   PubMed Web of Science ®Google Scholar
• Janowska-Wieczorek, A., Belch, A.R., et al. (1991) "Increased circulating colony-stimulating factor-1 in patients with preleukemia, leukemia, and lymphoid malignancies", Blood 77(8), 1796–1803.
   PubMed Web of Science ®Google Scholar
• Seidel, C., Borset, M., Hjertner-Hansen, H., et al. (1998) "Role of hepatocyte growth factor and its receptor c-met in multiple myeloma", Med. Oncol. 15, 145–153.
   PubMed Web of Science ®Google Scholar
• Mitsiades, N., Mitsiades, CS., Poulaki, V, et al. (2002) "Biologic sequelae of nuclear factor-KB blockade in multiple myeloma: therapeutic applications", Blood 99(11), 4079–4086.
   PubMed Web of Science ®Google Scholar
• Mitsiades, N., Mitsiades, CS., Poulaki, V, Anderson, K.C. and Treon, S.P. (2001) "Concepts in the use of TRAIL/Apo2L: an emerging biotherapy for myeloma and other neoplasias", Expert Opin. Investig. Drugs 10(8), 1521–1530.
   PubMed Web of Science ®Google Scholar
• Ogata, A., Chauhan, D., Teoh, G., et al. (1997) "IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade", J. Immunol. 159(5), 2212–2221.
   PubMed Web of Science ®Google Scholar
• Gilmore, T.D. (1999), "The Rel/NF-kappa B signal transduction pathway: introduction", Oncogene 18(49), 6842–6844.
   PubMed Web of Science ®Google Scholar
• Parman, T., Wiley, M.J. and Wells, P.G. (1999) "Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity", Nature Med. 5, 582–585.
   PubMed Web of Science ®Google Scholar
• Argiles, J.M., Cabo, N. and Lopez-Soriano, F.J. (1998) "Was tumour necrosis factor-alpha responsible for the foetal malformations associated with thalidomide in the early 1960's?", Med. Hypotheses 50, 313–318.
   PubMed Web of Science ®Google Scholar
• McBride, W.G. (1961) "Thalidomide and congenital abnor-malities", Lancet 2, 1358.
   Web of Science ®Google Scholar
• Kaplan, G. (2000) "Potential of thalidomide and thalidomide analogues as immunomodulatory drugs in leprosy and leprosy reactions", Lepr. Rev. 71 (Suppl.), S117—S120.
   PubMed Web of Science ®Google Scholar
• Hamurydan, V, Mat, C., Saip, S., et al. (1998) "Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double blind, placebo-controlled trial", Ann. Intern. Med. 128, 443–450.
   PubMed Web of Science ®Google Scholar
• Jacobson, J.M., Greenspan, J.S., Spritzler, J., et al. (1997) "Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection", N. Engl. J. Med. 336, 1487–1493.
   PubMed Web of Science ®Google Scholar
• Vogelsang, G.B., Farmer, E.R., Hess, A.D., et al. (1992) "Thalidomide for the treatment of chronic graft-versus-host disease", N. Engl. J. Med. 326(16), 1055–1058.
   PubMed Web of Science ®Google Scholar
• Singhal, S., Mehta, J., Desikan, R., et al. (1999) "Antitumour activity of thalidomide on refractory multiple myeloma", N. Engl. J. Med. 341, 1565–1571.
   PubMed Web of Science ®Google Scholar
• Raje, N. and Anderson, K. (1999) "Thalidomide—a revival story", N. Engl. J. Med. 341(21), 1606–1609.
   PubMed Web of Science ®Google Scholar
• Kyle, R.A. and Rajkumar, S.V. (2001) "Therapeutic application of thalidomide in multiple myeloma", Semin. Oncol. 28(6), 583–587.
   PubMed Web of Science ®Google Scholar
• Richardson, P., Hideshima, T. and Anderson, K. (2002) "Thalidomide in multiple myeloma", Biomed. Pharmacother. 56(3), 115–128.
   PubMed Web of Science ®Google Scholar
• Stirling, DJ. (2000) "Pharmacology of thalidomide", Semin. Haematol. 37, 5–14.
   PubMed Web of Science ®Google Scholar
• D'Amato, R.J., Loughnan, US., Flynn, E. and Folkman, J. (1994) "Thalidomide is an inhibitor of angiogenesis", Proc. Natl Acad. Sci. USA 91, 4082–4085.
   PubMed Web of Science ®Google Scholar
• Or, R., Feferman, R. and Shoshan, S. (1998) "Thalidomide reduces vascular density in granulation tissue of subcu-taneously implanted polyvinyl alcohol sponges in guinea pigs", Exp. Haematol. 26, 217–221.
   PubMed Web of Science ®Google Scholar
• Geitz, H., Handt, S. and Zwingenberger, K. (1996) "Thalido-mide selectively modulates the density of cell surface molecules involved in the adhesion cascade", Immunophar-macology 31, 213–221.
   PubMed Web of Science ®Google Scholar
• Neben, K., Moehler, T., Kraemer, A., Benner, A., Egerer, G., Ho, A.D. and Goldschmidt, H. (2001) "Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion", Br. J. Haematol. 115(3), 605–608.
   PubMed Web of Science ®Google Scholar
• Mitsiades, N., Mitsiades, CS., Poulaki, V, et al. (2002) "Apoptotic signaling induced by immunomodulatory thalidomide analogues (IMiDs) in human multiple mye-loma cells: therapeutic implications", Blood 99(12), 4525–4530.
   PubMed Web of Science ®Google Scholar
• Moreira, A.L., Sumpaio, E.P., Zmuidizinas, A., et al. (1993) "Thalidomide exerts its inhibitory action in tumour necrosis factor alpha by enhancing mRNA degradation", J. Exp. Med. 177, 1675–1680.
   PubMed Web of Science ®Google Scholar
• Turk, B.E., Jiang, H. and Lin, J.O. (1996) "Binding of thalidomide to alphal-acidglycoprotein may be involved in its inhibition of tumour necrosis factor alpha production", Proc. Natl Acad. Sci. USA 93, 7552–7556.
   PubMed Web of Science ®Google Scholar
• Wang, C.Y., Mayo, M.W. and Baldwin, Jr., A.S. (1996) "TNF-and cancer therapy-induced apoptosis; potentiation by inhibition of NF-kappaB", Science 274, 784–787.
   PubMed Web of Science ®Google Scholar
• Hideshima, T., Chauhan, D., Schlossman, R., et al. (2001) "The role of tumour necrosis factor in the pathophysiology of human multiple myeloma: therapeutic applications", Onco-gene 20, 4519–4527.
   Web of Science ®Google Scholar
• Haslett, P.A., Corral, L.G., Albert, M. and Kaplan, G. (1998) "Thalidomide co-stimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production and cytotoxic responses in the CD8 + subsets", J. Exp. Med. 187, 1885–1892.
   PubMed Web of Science ®Google Scholar
• Mettagh, S.M., Rifkin, JR., Deighton, J., et al. (1995) "The immunosuppressive drug thalidomide induces T helper cell type 2 (TL2) and concomitantly inhibits Th1 cytokine production in mitogen and antigen-stimulated human peripheral blood mononuclear cell cultures", Clin. Med. Immunol. 99, 160–167.
   Web of Science ®Google Scholar
• Davies, RE., Raje, N., Hideshima, T., et al. (2000) "Thalido-mide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma", Blood 98, 210–216.
   Web of Science ®Google Scholar
• Singhal, S., Mehta, J. and Desikan, R. (1999) "Antitumor activity of thalidomide in refractory multiple myeloma", N. Engl. J. Med. 341(21), 1565–1571.
   PubMed Web of Science ®Google Scholar
• Rajkumar, S.V. (2001) "Thalidomide in the treatment of multiple myeloma", Expert Rev. Anticancer Ther. 1(1), 20–28.
   PubMedGoogle Scholar
• Juliusson, G., Celsing, E., Turesson, I., Adriansson, M. and Malm, C. (2000) "Thalidomide frequently induces good partial remission and best response ever in patients with advanced multiple myeloma and prior high dose melphalan and autotransplant", Br. J. Haematol. 109, 89.
   PubMed Web of Science ®Google Scholar
• Kneller, A., Roanani, P., Hardan, I., et al. (2000) "Therapy with thalidomide in refractory multiple myeloma. The revival of an old drug", Br. J. Haematol. 109, 89.
   PubMed Web of Science ®Google Scholar
• Barlogie, B., Spencer, T., Tricot, G., et al. (2000) "Long term follow up of 169 patients receiving a Phase II trial of single agent thalidomide for advanced and refractory multiple myeloma", Blood 96\(Suppl. 1), 514a.
   PubMedGoogle Scholar
• Schey, S.A., Jones, R.W., Cavenagh, J., et al. (2002) "Thalidomide in relapsed/refractory multiple myeloma: a UK Myeloma Forum study: 6-, 9-, and 12-month results", JCO(Suppl 1), 21, 276a.
   Google Scholar
• Rajkumar, S.V., Dispenzieri, A., Fonseca, R., et al. (2001) "Thalidomide for previously untreated indolent or smolder-ing multiple myeloma", Leukemia 15(8), 1274–1276.
   PubMed Web of Science ®Google Scholar
• Weber, D.M., Gavino, M., Delasalle, K., Rankin, K., Giralt, S. and Alexarian, R. (1999) "Thalidomide alone or with dexamethasone for multiple myeloma", Blood 94\(Suppl. 1), 604a.
   Google Scholar
• Dimopoulos, M.A., Zervas, K., Kouvatseas, G., et al. (2001) "Thalidomide and dexamethasone combination for refractory multiple myeloma", Ann. Oncol. 12(7), 991–995.
   PubMed Web of Science ®Google Scholar
• Kropff, M.H., Innig, G., Mitterer, M., et al. (2000) "Hyper-fractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (Hyper-CDT) in primary refractory or relapsed multiple myeloma", Blood 96 (Suppl. 1), 168a.
   Google Scholar
• Moehler, T.M., Neben, K., Benner, A., et al. (2001) "Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy", Blood 98(13), 3846–3848.
   PubMed Web of Science ®Google Scholar
• Corral, L.G., Haslett, P.A., Muller, G.W., et al. (1999) "Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-et", J. Immunol. 163,380–386.
   PubMed Web of Science ®Google Scholar
• Muller, G.W., Chen, R., Huang, S.Y., Corral, L.G., Wong, L.M., Patterson, R.T., Chen, Y., Kaplan, G. and Stirling, DJ. (1999) "Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production", Bioorg. Med. Chem. Lett. 9, 1625–1630.
   PubMed Web of Science ®Google Scholar
• Muller, G.W., Corral, L.G., Shire, M.G., et al. (1996) "Structural modifications of thalidomide produce analogues with enhanced tumour necrosis factor inhibitory activity", L Med. Chem. 39, 3238–3240.
   Web of Science ®Google Scholar
• Corral, L.G., Muller, G.W., Moreire, A.L., et al. (1999) "Selection of novel analogues of thalidomide with enhanced tumour necrosis factor-alpha inhibitory activity", Mol. Med. 2, 506–515.
   Google Scholar
• Schey, S.A., Jones, R.W., Raj, K. and Streetley, M. (2002) "A phase I study of an immunomodulatory drug (CC 4047), a structural analogue of thalidomide in relapsed/refractory multiple myeloma", J. Exp. Haematol. (Suppl. 1), 30(6), 98.
   Google Scholar
• Zangari, M., Tricot, G., Zeldis, J. et al. (2001) "Results of a phase I study of CC5013 for the treatment of multiple myeloma patients who relapse after high dose chemother-apy" Presented at Am. Soc. Haematol. 43rd Annual meeting, Orlando, FL, Dec 7–11.
   Google Scholar
• Dune, B.G.M. and Stepan, D.E. (1999) "Efficacy of low dose thalidomide (T) in multiple myeloma", Blood (Suppl. 1) 316a.
   Google Scholar
• Johnston, R.E. and Abdalla, S.H. (2002) "Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia", Leuk. Lymphoma 43(2), 351–354.
   PubMed Web of Science ®Google Scholar
• Barlogie, B., Jagannath, S., Desikan, KR., et al. (1999) "Total therapy with tandem transplants for newly diagnosed multiple myeloma", Blood 93, 55–65.
   PubMed Web of Science ®Google Scholar
• Urbauer, E., Kaufmann, H., Nosslinger, T., et al. (2002) "Thromboembolic events during treatment with thalido-mide", Blood 99(11), 4247–4248.
   PubMed Web of Science ®Google Scholar
• Osman, K., Comenzo, R. and Rajkumar, S.V. (2001) "Deep venous thrombosis and thalidomide therapy for multiple myeloma", N. Engl. J. Med. 344(25), 1951–1952.
   PubMed Web of Science ®Google Scholar
• Zangari, M., Siegel, E., Barlogie, B., et al. (2002) "Thrombo-genic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy", Blood 100(4), 1168–1171.
   PubMed Web of Science ®Google Scholar